State of the Art: Multidisciplinary Management of Oligometastatic Renal Cell Carcinoma

作者：Shawn Dason, Kristine Peregrino Lacuna, Raquibul Hannan, Eric A. Singer, Karie D. Runcie · 发表于：American Society of Clinical Oncology Educational Book · 年份：2023 · DOI：10.1200/edbk_390038 · 被引用次数：38 · 研究领域：Renal cell carcinoma treatment、Renal and related cancers、Cancer Genomics and Diagnostics

Oligometastatic renal cell carcinoma (OM-RCC) refers to patients who have limited (typically up to 5) metastatic lesions. Although management principles may overlap, OM-RCC is distinguishable from oligoprogressive RCC, which describes progression of disease to a limited number of sites while receiving systemic therapy. Cytoreductive nephrectomy and metastasectomy are common surgical considerations in OM-RCC, and indications are discussed in this review. It is evident that stereotactic ablative radiotherapy is effective in RCC and is being applied increasingly in the oligometastatic setting. Finally, we will review advances in systemic therapy and the role of active surveillance before the initiation of systemic therapy.